<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1486" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1486/" /><meta name="ncbi_pagename" content="Pyridoxine-Dependent Epilepsy - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Pyridoxine-Dependent Epilepsy - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Pyridoxine-Dependent Epilepsy" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2017/04/13" /><meta name="citation_author" content="Sidney M Gospe, Jr" /><meta name="citation_pmid" content="20301659" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1486/" /><meta name="citation_keywords" content="Pyridoxine Dependency" /><meta name="citation_keywords" content="Pyridoxine-Dependent Seizures" /><meta name="citation_keywords" content="Vitamin B6-Dependent Seizures" /><meta name="citation_keywords" content="Pyridoxine Dependency" /><meta name="citation_keywords" content="Vitamin B6-Dependent Seizures" /><meta name="citation_keywords" content="Pyridoxine-Dependent Seizures" /><meta name="citation_keywords" content="Alpha-aminoadipic semialdehyde dehydrogenase" /><meta name="citation_keywords" content="ALDH7A1" /><meta name="citation_keywords" content="Pyridoxine-Dependent Epilepsy" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Pyridoxine-Dependent Epilepsy" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Sidney M Gospe, Jr" /><meta name="DC.Date" content="2017/04/13" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1486/" /><meta name="description" content="Pyridoxine-dependent epilepsy is characterized by intractable seizures within the first weeks to months of life that are not controlled with antiepileptic drugs but respond both clinically and electrographically to large daily supplements of pyridoxine (vitamin B6). Multiple types of clinical seizures have been reported in individuals with pyridoxine-dependent epilepsy. Dramatic presentations consisting of prolonged seizures and recurrent episodes of status epilepticus are typical; recurrent self-limited events including partial seizures, generalized seizures, atonic seizures, myoclonic events, and infantile spasms also occur. Affected individuals may have electrographic seizures without clinical correlates. Infants with the classic neonatal presentation begin to experience seizures soon after birth. Atypical features include: late-onset seizures (seizures that begin from late infancy up until age 3 years); seizures that initially respond to antiepileptic drugs and then become intractable; seizures during early life that do not respond to pyridoxine but are then controlled with pyridoxine several months later; and prolonged seizure-free intervals (≤5.5 months) that occur after discontinuation of pyridoxine. Intellectual disability is common." /><meta name="og:title" content="Pyridoxine-Dependent Epilepsy" /><meta name="og:type" content="book" /><meta name="og:description" content="Pyridoxine-dependent epilepsy is characterized by intractable seizures within the first weeks to months of life that are not controlled with antiepileptic drugs but respond both clinically and electrographically to large daily supplements of pyridoxine (vitamin B6). Multiple types of clinical seizures have been reported in individuals with pyridoxine-dependent epilepsy. Dramatic presentations consisting of prolonged seizures and recurrent episodes of status epilepticus are typical; recurrent self-limited events including partial seizures, generalized seizures, atonic seizures, myoclonic events, and infantile spasms also occur. Affected individuals may have electrographic seizures without clinical correlates. Infants with the classic neonatal presentation begin to experience seizures soon after birth. Atypical features include: late-onset seizures (seizures that begin from late infancy up until age 3 years); seizures that initially respond to antiepileptic drugs and then become intractable; seizures during early life that do not respond to pyridoxine but are then controlled with pyridoxine several months later; and prolonged seizure-free intervals (≤5.5 months) that occur after discontinuation of pyridoxine. Intellectual disability is common." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1486/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/pds/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1486/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE88CCE1E0409AD10000000006FF02B2.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1486_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1486_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/pf/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/pdc/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1486_"><span class="title" itemprop="name">Pyridoxine-Dependent Epilepsy</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonyms: Pyridoxine Dependency, Pyridoxine-Dependent Seizures, Vitamin B<sub>6</sub>-Dependent Seizures</div><p class="contrib-group"><span itemprop="author">Sidney M Gospe, Jr</span>, MD, PhD.</p><a data-jig="ncbitoggler" href="#__NBK1486_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1486_ai__"><div class="contrib half_rhythm"><span itemprop="author">Sidney M Gospe, Jr</span>, MD, PhD<div class="affiliation small">Herman and Faye Sarkowsky Endowed Chair of Child Neurology<br />Professor, Neurology and Pediatrics<br />University of Washington School of Medicine<br />Seattle, Washington<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.wu@epsogs" class="oemail">ude.wu@epsogs</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">December 7, 2001</span>; Last Update: <span itemprop="dateModified">April 13, 2017</span>.</p><p><em>Estimated reading time: 26 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="pds.Summary" itemprop="description"><h2 id="_pds_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Pyridoxine-dependent epilepsy is characterized by intractable seizures within the first weeks to months of life that are not controlled with antiepileptic drugs but respond both clinically and electrographically to large daily supplements of pyridoxine (vitamin B<sub>6</sub>). Multiple types of clinical seizures have been reported in individuals with pyridoxine-dependent epilepsy. Dramatic presentations consisting of prolonged seizures and recurrent episodes of status epilepticus are typical; recurrent self-limited events including partial seizures, generalized seizures, atonic seizures, myoclonic events, and infantile spasms also occur. Affected individuals may have electrographic seizures without clinical correlates. Infants with the classic neonatal presentation begin to experience seizures soon after birth. Atypical features include: late-onset seizures (seizures that begin from late infancy up until age 3 years); seizures that initially respond to antiepileptic drugs and then become intractable; seizures during early life that do not respond to pyridoxine but are then controlled with pyridoxine several months later; and prolonged seizure-free intervals (&#x02264;5.5 months) that occur after discontinuation of pyridoxine. Intellectual disability is common.</p><p>Elevated concentration of &#x003b1;-aminoadipic semialdehyde (&#x003b1;-AASA) in urine and plasma is a strong biomarker of the disorder; pipecolic acid may also be elevated in plasma and cerebrospinal fluid.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of pyridoxine-dependent epilepsy is established in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>: (a) showing a clinical response to pyridoxine administration followed by biochemical testing showing the presence of biomarkers; and/or (b) by the identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>ALDH7A1.</i> Clinical diagnosis may be made in individuals experiencing status epilepticus or repetitive clinical seizures that are not controlled with antiepileptic drugs by concurrently administering 100 mg of pyridoxine intravenously while monitoring the EEG, oxygen saturation, and vital signs. In individuals with pyridoxine-dependent epilepsy, clinical seizures generally cease over several minutes. If a clinical response is not demonstrated, the dose should be repeated up to a maximum of 500 mg. A corresponding change should be observed in the EEG, although it may be delayed by several hours. Alternatively, in children who experience frequent antiepileptic drug-resistant self-limited seizures, oral pyridoxine at a dose of 30 mg/kg/day may be initiated. Children who are pyridoxine dependent should have a resolution of their clinical seizures within three to seven days.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Pyridoxine-dependent epilepsy is initially controlled with the addition of daily supplements of pyridoxine; subsequently, in the majority of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals all antiepileptic drugs can be withdrawn and seizure control continued with daily pyridoxine monotherapy in pharmacologic doses. To prevent exacerbation of clinical seizures and/or encephalopathy during an acute illness, the daily dose of pyridoxine may be doubled for several days. Special education programs are offered to affected individuals.</p><p><i>Prevention of secondary complications:</i> Overuse of pyridoxine can cause a reversible sensory neuropathy.</p><p><i>Surveillance</i>: Monitoring for development of clinical signs of a sensory neuropathy and regular assessments of intellectual function.</p><p><i>Evaluation of relatives at risk:</i></p><ul><li class="half_rhythm"><div>If the pathogenic variants in the family are known, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of at-risk newborn sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> for early diagnosis and treatment to reduce morbidity and mortality.</div></li><li class="half_rhythm"><div>If the pathogenic variants in the family are not known and the at-risk sib is experiencing clinical seizures or encephalopathy, administration of pyridoxine acutely (under EEG monitoring) for diagnostic and therapeutic purposes.</div></li></ul><p><i>Pregnancy management</i>: Supplemental maternal pyridoxine at a dose of 50-100 mg per day throughout the last half of pregnancy and after birth may be considered if the fetus is known to be <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or, if diagnostic prenatal testing is not pursued, in an at-risk fetus and neonate, until the diagnosis has been ruled out.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>Pyridoxine-dependent epilepsy is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner. At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier. Carrier testing for at-risk relatives and <a class="def" href="/books/n/gene/glossary/def-item/prenatal-diagnosis/">prenatal diagnosis</a> for pregnancies at increased risk are possible if both pathogenic variants in a family are known.</p></div></div><div id="pds.Diagnosis"><h2 id="_pds_Diagnosis_">Diagnosis</h2><div id="pds.Suggestive_Findings"><h3>Suggestive Findings</h3><p>Pyridoxine-dependent epilepsy <b>should be suspected</b> in individuals with the following clinical, family history, and supportive laboratory findings.</p><p><b>Clinical features</b></p><ul><li class="half_rhythm"><div>Seizures in any child under age one year without an apparent brain malformation as the cause of the epilepsy</div></li><li class="half_rhythm"><div>Cryptogenic seizures in a previously normal infant without an abnormal gestational or perinatal history</div></li><li class="half_rhythm"><div>Neonates with a <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> suggestive of hypoxic ischemic encephalopathy and with difficult-to-control seizures</div></li><li class="half_rhythm"><div>The occurrence of long-lasting focal or unilateral seizures, often with partial preservation of consciousness</div></li><li class="half_rhythm"><div>Infants and children with seizures that are partially responsive to antiepileptic drugs, in particular if associated with developmental delay and intellectual disability</div></li><li class="half_rhythm"><div>Irritability, restlessness, crying, and vomiting preceding the actual seizures</div></li><li class="half_rhythm"><div>Individuals with a history of transient or unclear response of seizures to pyridoxine</div></li><li class="half_rhythm"><div>Infants and children with a history of seizures responsive to folinic acid</div></li></ul><p><b>Family history</b></p><ul><li class="half_rhythm"><div>A severe convulsive disorder in a sib, often leading to death during status epilepticus</div></li><li class="half_rhythm"><div>Parental <a class="def" href="/books/n/gene/glossary/def-item/consanguinity/">consanguinity</a></div></li></ul><p><b>Supportive laboratory findings</b></p><ul><li class="half_rhythm"><div class="half_rhythm">Elevated plasma and urinary alpha-aminoadipic semialdehyde (&#x003b1;-AASA)</div></li><li class="half_rhythm"><div class="half_rhythm">Elevated concentrations of <b>pipecolic acid</b> in plasma and cerebral spinal fluid</div><div class="half_rhythm">Note: Pipecolic acid concentrations may normalize after many years of therapy [<a class="bk_pop" href="#pds.REF.plecko.2005.200">Plecko et al 2005</a>].</div></li><li class="half_rhythm"><div class="half_rhythm">Analysis of cerebrospinal fluid <b>monoamine metabolites</b> via HPLC with electrochemical detection demonstrating:</div><ul><li class="half_rhythm"><div>A pattern characteristic of pyridoxine-dependent epilepsy containing two peaks of unknown identity [<a class="bk_pop" href="#pds.REF.gallagher.2009.550">Gallagher et al 2009</a>];</div></li><li class="half_rhythm"><div>A characteristic chromatographic pattern of folinic acid-responsive seizures [<a class="bk_pop" href="#pds.REF.hyland.1995.177">Hyland et al 1995</a>, <a class="bk_pop" href="#pds.REF.torres.1999.529">Torres et al 1999</a>, <a class="bk_pop" href="#pds.REF.nicolai.2006.164">Nicolai et al 2006</a>].</div></li></ul></li><li class="half_rhythm"><div class="half_rhythm"><b>Newborn screening.</b> The biomarker AASA has been shown to be present in blood specimens (newborn blood spots) from neonates subsequently diagnosed with pyridoxine-dependent epilepsy [<a class="bk_pop" href="#pds.REF.jung.2013.237">Jung et al 2013</a>]. However, <a class="def" href="/books/n/gene/glossary/def-item/newborn-screening/">newborn screening</a> for pyridoxine-dependent epilepsy is currently not available on a clinical basis.</div></li></ul></div><div id="pds.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of pyridoxine-dependent epilepsy <b>is established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> showing a clinical response to pyridoxine administration, followed by biochemical testing showing the presence of biomarkers; and/or by the identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>ALDH7A1</i> (see <a class="figpopup" href="/books/NBK1486/table/pds.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="figpdsTmoleculargenetictestingusedin" rid-ob="figobpdsTmoleculargenetictestingusedin">Table 1</a>).</p><p><b>A clinical diagnosis</b> may be made:</p><ul><li class="half_rhythm"><div>On an acute basis in individuals experiencing clinical seizures by concurrently administering 100 mg of pyridoxine intravenously while monitoring the EEG, oxygen saturation, and vital signs [<a class="bk_pop" href="#pds.REF.baxter.2001.416">Baxter 2001</a>, <a class="bk_pop" href="#pds.REF.stockler.2011.48">Stockler et al 2011</a>]:</div><ul><li class="half_rhythm"><div>In individuals with pyridoxine-dependent epilepsy, clinical seizures generally cease over a period of several minutes.</div></li><li class="half_rhythm"><div>If a clinical response is not demonstrated, the dose should be repeated up to a maximum of 500 mg.</div></li><li class="half_rhythm"><div>A corresponding change should be observed in the EEG; in some circumstances, the change may be delayed by several hours.</div></li><li class="half_rhythm"><div>In some individuals with pyridoxine-dependent epilepsy, significant neurologic and cardiorespiratory depression follows this trial, making close systemic monitoring essential.</div></li></ul></li><li class="half_rhythm"><div>By administering 30 mg/kg/day of pyridoxine orally. In individuals with pyridoxine-dependent epilepsy, clinical seizures should cease within three to five days [<a class="bk_pop" href="#pds.REF.baxter.2001.416">Baxter 2001</a>, <a class="bk_pop" href="#pds.REF.gospe.2006.148">Gospe 2006</a>, <a class="bk_pop" href="#pds.REF.stockler.2011.48">Stockler et al 2011</a>].</div></li></ul><p>Note: In the past, the clinical diagnosis of pyridoxine-dependent epilepsy was confirmed by withdrawing antiepileptic drugs, followed by the withdrawal of daily pyridoxine supplementation and then successfully treating a recurrence of seizures with pyridoxine. Now that measurement of biomarkers supportive of a diagnosis of pyridoxine-dependent epilepsy is clinically available, this sequence of therapeutic changes is not necessary. In an individual with a clinical <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> suggestive of pyridoxine-dependent epilepsy, daily pyridoxine supplementation should be continued while biomarker testing is pursued.</p><p>Molecular genetic testing approaches can include <b>single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b> and use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing.</b> Sequence analysis of <i>ALDH7A1</i> is performed first and followed by gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> if only one or no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is found.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>ALDH7A1</i> and other genes of interest (see <a href="#pds.Differential_Diagnosis">Differential Diagnosis</a>) may also be considered. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</div><div class="half_rhythm">For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</div></li></ul><div id="pds.T.molecular_genetic_testing_used_in" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Pyridoxine-Dependent Epilepsy</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1486/table/pds.T.molecular_genetic_testing_used_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__pds.T.molecular_genetic_testing_used_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_pds.T.molecular_genetic_testing_used_in_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_pds.T.molecular_genetic_testing_used_in_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Test Method</th><th id="hd_h_pds.T.molecular_genetic_testing_used_in_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with Pathogenic Variants&#x000a0;<sup>2</sup> Detectable by This Method</th></tr></thead><tbody><tr><td headers="hd_h_pds.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>ALDH7A1</i></td><td headers="hd_h_pds.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3</sup></td><td headers="hd_h_pds.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">99/100&#x000a0;<sup>4</sup></td></tr><tr><td headers="hd_h_pds.T.molecular_genetic_testing_used_in_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>5</sup></td><td headers="hd_h_pds.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">8 individuals with <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions&#x000a0;<sup>4</sup></td></tr><tr><td headers="hd_h_pds.T.molecular_genetic_testing_used_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&#x000a0;<sup>6</sup></td><td headers="hd_h_pds.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">NA</td><td headers="hd_h_pds.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="pds.TF.1.1"><p class="no_margin">See <a href="/books/NBK1486/#pds.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="pds.TF.1.2"><p class="no_margin">See <a href="#pds.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="pds.TF.1.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="pds.TF.1.4"><p class="no_margin">99 /100 families with individuals with both clinical and biomarker evidence of pyridoxine-dependent epilepsy had two identifiable pathogenic variants identified by <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> or <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> analysis. Of these 99 kindreds, 91 <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals had two pathogenic variants identified by sequence analysis [<a class="bk_pop" href="#pds.REF.mills.2006.307">Mills et al 2006</a>, <a class="bk_pop" href="#pds.REF.kanno.2007.384">Kanno et al 2007</a>, <a class="bk_pop" href="#pds.REF.plecko.2007.19">Plecko et al 2007</a>, <a class="bk_pop" href="#pds.REF.bennett.2009.1167">Bennett et al 2009</a>, <a class="bk_pop" href="#pds.REF.mills.2010.2148">Mills et al 2010</a>, <a class="bk_pop" href="#pds.REF.scharer.2010.571">Scharer et al 2010</a>, <a class="bk_pop" href="#pds.REF.p_rez.2013.239">P&#x000e9;rez et al 2013</a>]. Seven additional affected individuals had one <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> identified by sequence analysis with the second variant demonstrated by deletion/deletion analysis [<a class="bk_pop" href="#pds.REF.kanno.2007.384">Kanno et al 2007</a>, <a class="bk_pop" href="#pds.REF.plecko.2007.19">Plecko et al 2007</a>, <a class="bk_pop" href="#pds.REF.mefford.2015.756">Mefford et al 2015</a>]. One affected individual had <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> large deletions [<a class="bk_pop" href="#pds.REF.p_rez.2013.239">P&#x000e9;rez et al 2013</a>]. The one final affected individual with confirmed pyridoxine-dependent epilepsy had one pathogenic variant identified by sequence analysis and no second variant identified by either sequence analysis or <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> [<a class="bk_pop" href="#pds.REF.kluger.2008.276">Kluger et al 2008</a>, <a class="bk_pop" href="#pds.REF.mefford.2015.756">Mefford et al 2015</a>].</p></div></dd><dt>5. </dt><dd><div id="pds.TF.1.5"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include: <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>6. </dt><dd><div id="pds.TF.1.6"><p class="no_margin">Evidence for <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> heterogeneity: <br />a. Assignment to the <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> 5q31 pyridoxine-dependent epilepsy locus was excluded on the basis of haplotype analysis in one of the six North American pyridoxine-dependent epilepsy pedigrees. The <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> children in the family had late-onset infantile spasms responsive to pyridoxine therapy [<a class="bk_pop" href="#pds.REF.bennett.2005.143">Bennett et al 2005</a>]. A later study failed to detect <i>ALDH7A1</i> pathogenic variants in these children and in two additional children presenting with pyridoxine-responsive late-onset infantile spasms [<a class="bk_pop" href="#pds.REF.bennett.2009.1167">Bennett et al 2009</a>].<br />b. Very late-onset pyridoxine-dependent epilepsy presented in a female age eight years in whom linkage to the 5q31 locus was excluded by haplotype analysis [<a class="bk_pop" href="#pds.REF.kabakus.2008.703">Kabakus et al 2008</a>].<br />c. Individuals with neonatal-onset pyridoxine-dependent epilepsy resulting from <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>PROSC</i> have been described (see <a href="#pds.Differential_Diagnosis">Differential Diagnosis</a>) [<a class="bk_pop" href="#pds.REF.darin.2016.1325">Darin et al 2016</a>].</p></div></dd></dl></div></div></div></div></div><div id="pds.Clinical_Characteristics"><h2 id="_pds_Clinical_Characteristics_">Clinical Characteristics</h2><div id="pds.Clinical_Description"><h3>Clinical Description</h3><p>The one clinical feature characteristic of all individuals with pyridoxine-dependent epilepsy is intractable seizures that are not controlled with antiepileptic drugs but that respond both clinically and electrographically to large daily supplements of pyridoxine.</p><div id="pds.Classic_PyridoxineDependent_Epilepsy"><h4>Classic Pyridoxine-Dependent Epilepsy</h4><p>Multiple types of clinical seizures have been reported in individuals with pyridoxine-dependent epilepsy. Although dramatic presentations consisting of prolonged seizures and recurrent episodes of status epilepticus are typical, recurrent self-limited events including partial, generalized, and atonic seizures; myoclonic events; and infantile spasms also occur. Affected individuals may have electrographic seizures without clinical correlates.</p><p>Newborns with the classic neonatal presentation begin to experience seizures soon after birth.</p><ul><li class="half_rhythm"><div>In retrospect, many mothers recount unusual intrauterine movements that may have started in the late second trimester and that likely represent fetal seizures [<a class="bk_pop" href="#pds.REF.baxter.2001.416">Baxter 2001</a>].</div></li><li class="half_rhythm"><div>Affected neonates frequently have periods of encephalopathy (irritability, crying, fluctuating tone, poor feeding) that precede the onset of clinical seizures. Low Apgar scores, abnormal cord blood gases, and other abnormalities of blood chemistries may also be observed. For this reason, it is not uncommon for these newborns to be diagnosed with hypoxic-ischemic encephalopathy [<a class="bk_pop" href="#pds.REF.baxter.1999.431">Baxter 1999</a>, <a class="bk_pop" href="#pds.REF.mills.2010.2148">Mills et al 2010</a>, <a class="bk_pop" href="#pds.REF.van_karnebeek.2016.6">van Karnebeek et al 2016</a>].</div></li><li class="half_rhythm"><div>Clinical seizures may be associated with facial grimacing and abnormal eye movements [<a class="bk_pop" href="#pds.REF.schmitt.2010.e133">Schmitt et al 2010</a>].</div></li></ul><p>Similar periods of encephalopathy may be seen in older infants with pyridoxine-dependent epilepsy, particularly prior to recurrence of clinical seizures, which occur in children treated with pyridoxine whose vitamin requirement may have increased because of growth or intercurrent infection, particularly gastroenteritis.</p><p>Intellectual disability, particularly with expressive language, is common in individuals with pyridoxine-dependent epilepsy.</p><ul><li class="half_rhythm"><div>It has been suggested that an earlier onset of clinical seizures corresponds to a worse prognosis for cognitive function, and the length of the delay in diagnosis and initiation of effective pyridoxine treatment correlates with increased handicaps [<a class="bk_pop" href="#pds.REF.baxter.2001.416">Baxter 2001</a>, <a class="bk_pop" href="#pds.REF.kluger.2008.276">Kluger et al 2008</a>, <a class="bk_pop" href="#pds.REF.basura.2009.697">Basura et al 2009</a>].</div></li><li class="half_rhythm"><div>Seizures in some individuals with molecularly confirmed pyridoxine-dependent epilepsy are incompletely controlled with pyridoxine, and concurrent treatment with one or more antiepileptic drugs is required. Significant intellectual disability is present in these individuals [<a class="bk_pop" href="#pds.REF.basura.2009.697">Basura et al 2009</a>, <a class="bk_pop" href="#pds.REF.scharer.2010.571">Scharer et al 2010</a>].</div></li><li class="half_rhythm"><div>Some <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals with normal intellectual function have been reported [<a class="bk_pop" href="#pds.REF.ohtsuka.1999.203">Ohtsuka et al 1999</a>, <a class="bk_pop" href="#pds.REF.basura.2009.697">Basura et al 2009</a>, <a class="bk_pop" href="#pds.REF.bok.2012.849">Bok et al 2012</a>, <a class="bk_pop" href="#pds.REF.van_karnebeek.2016.6">van Karnebeek et al 2016</a>].</div></li><li class="half_rhythm"><div>Few formal psychometric assessments in individuals with pyridoxine-dependent epilepsy have been performed. These limited studies have inconsistent findings. Two earlier studies indicate that verbal skills are more impaired than nonverbal skills [<a class="bk_pop" href="#pds.REF.baxter.1996.998">Baxter et al 1996</a>, <a class="bk_pop" href="#pds.REF.baynes.2003.782">Baynes et al 2003</a>] while a more recent report suggests that verbal IQ is slightly (but not significantly) higher than performance IQ [<a class="bk_pop" href="#pds.REF.bok.2012.849">Bok et al 2012</a>].</div></li></ul></div><div id="pds.Atypical_PyridoxineDependent_Epileps"><h4>Atypical Pyridoxine-Dependent Epilepsy</h4><p>Late-onset and other atypical features of this phenotypically heterogeneous disorder have been described [<a class="bk_pop" href="#pds.REF.gouti_res.1985.117">Gouti&#x000e8;res &#x00026; Aicardi 1985</a>, <a class="bk_pop" href="#pds.REF.coker.1992.221">Coker 1992</a>, <a class="bk_pop" href="#pds.REF.basura.2009.697">Basura et al 2009</a>, <a class="bk_pop" href="#pds.REF.van_karnebeek.2016.6">van Karnebeek et al 2016</a>]. These include:</p><ul><li class="half_rhythm"><div>Late-onset seizures (seizures that begin during late infancy up until age 3 years)</div></li><li class="half_rhythm"><div>Seizures that initially respond to antiepileptic drugs and then become intractable</div></li><li class="half_rhythm"><div>Seizures during early life that do not respond to pyridoxine but that are then controlled with pyridoxine several months later</div></li><li class="half_rhythm"><div>Prolonged seizure-free intervals (age &#x02264;5.5 months) that occur after pyridoxine discontinuation</div></li></ul></div><div id="pds.EEGNeuroimaging"><h4>EEG/Neuroimaging</h4><p>While a variety of EEG abnormalities have been described in individuals with pyridoxine-dependent epilepsy, none is pathognomonic for this condition [<a class="bk_pop" href="#pds.REF.mikati.1991.215">Mikati et al 1991</a>, <a class="bk_pop" href="#pds.REF.nabbout.1999.f125">Nabbout et al 1999</a>, <a class="bk_pop" href="#pds.REF.naasan.2009.293">Naasan et al 2009</a>, <a class="bk_pop" href="#pds.REF.bok.2010b.2406">Bok et al 2010b</a>, <a class="bk_pop" href="#pds.REF.mills.2010.2148">Mills et al 2010</a>, <a class="bk_pop" href="#pds.REF.schmitt.2010.e133">Schmitt et al 2010</a>].</p><p>Several imaging abnormalities have been reported in individuals with pyridoxine-dependent epilepsy:</p><ul><li class="half_rhythm"><div>Thinning of the corpus callosum (greatest in the isthmus and more rostral callosum) is universally seen [<a class="bk_pop" href="#pds.REF.friedman.2014.1106">Friedman et al 2014</a>, <a class="bk_pop" href="#pds.REF.poliachik.2016.43">Poliachik et al 2016</a>].</div></li><li class="half_rhythm"><div>Mega cisterna magma has been reported in a number of instances [<a class="bk_pop" href="#pds.REF.baxter.1996.998">Baxter et al 1996</a>, <a class="bk_pop" href="#pds.REF.mills.2010.2148">Mills et al 2010</a>, <a class="bk_pop" href="#pds.REF.friedman.2014.1106">Friedman et al 2014</a>].</div></li></ul></div></div><div id="pds.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>More than 80 <i>ALDH7A1</i> sequence alterations have been documented in both neonatal-onset and late-onset cases; however, no firm <a class="def" href="/books/n/gene/glossary/def-item/genotype-phenotype-correlations/">genotype-phenotype correlations</a> are known [<a class="bk_pop" href="#pds.REF.mills.2006.307">Mills et al 2006</a>, <a class="bk_pop" href="#pds.REF.kanno.2007.384">Kanno et al 2007</a>, <a class="bk_pop" href="#pds.REF.plecko.2007.19">Plecko et al 2007</a>, <a class="bk_pop" href="#pds.REF.rankin.2007.300">Rankin et al 2007</a>, <a class="bk_pop" href="#pds.REF.salomons.2007.414">Salomons et al 2007</a>, <a class="bk_pop" href="#pds.REF.bennett.2009.1167">Bennett et al 2009</a>, <a class="bk_pop" href="#pds.REF.striano.2009.933">Striano et al 2009</a>, <a class="bk_pop" href="#pds.REF.mills.2010.2148">Mills et al 2010</a>, <a class="bk_pop" href="#pds.REF.scharer.2010.571">Scharer et al 2010</a>, <a class="bk_pop" href="#pds.REF.stockler.2011.48">Stockler et al 2011</a>, <a class="bk_pop" href="#pds.REF.bok.2012.849">Bok et al 2012</a>, <a class="bk_pop" href="#pds.REF.p_rez.2013.239">P&#x000e9;rez et al 2013</a>, <a class="bk_pop" href="#pds.REF.tlili.2013.242">Tlili et al 2013</a>, <a class="bk_pop" href="#pds.REF.van_karnebeek.2015">van Karnebeek &#x00026; Gospe 2015</a>, <a class="bk_pop" href="#pds.REF.mefford.2015.756">Mefford et al 2015</a>, <a class="bk_pop" href="#pds.REF.van_karnebeek.2016.6">van Karnebeek et al 2016</a>].</p><p>The "common" p.Glu399Gln <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 14 (see <a href="#pds.Molecular_Genetics">Molecular Genetics</a>, <b>Pathogenic variants</b>) is responsible for approximately 30% of the mutated alleles. This pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variant has been observed in both neonatal- and late-onset cases [<a class="bk_pop" href="#pds.REF.bennett.2009.1167">Bennett et al 2009</a>].</p><p>Pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants that result in residual enzyme activity may be associated with a more favorable developmental <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> [<a class="bk_pop" href="#pds.REF.scharer.2010.571">Scharer et al 2010</a>].</p></div><div id="pds.Prevalence"><h3>Prevalence</h3><p>First described by <a class="bk_pop" href="#pds.REF.hunt.1954.140">Hunt et al [1954]</a>, pyridoxine-dependent epilepsy is generally considered to be a rare cause of intractable neonatal seizures. Prior to the discovery of the biochemical and genetic abnormalities underlying pyridoxine-dependent epilepsy, approximately 100 <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals had been reported [<a class="bk_pop" href="#pds.REF.baxter.1999.431">Baxter 1999</a>]. Subsequently, <i>ALDH7A1</i> <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> has been conducted and reported on many of these individuals along with several others.</p><p>A few epidemiologic studies of this condition have been conducted.</p><ul><li class="half_rhythm"><div>In the northern part of the United Kingdom, the prevalence of pyridoxine-dependent epilepsy in children younger than age 16 years was estimated at 1:100,000 [<a class="bk_pop" href="#pds.REF.baxter.1996.998">Baxter et al 1996</a>].</div></li><li class="half_rhythm"><div>National studies in the United Kingdom and the Republic of Ireland noted a prevalence of approximately 1:700,000 [<a class="bk_pop" href="#pds.REF.baxter.1999.431">Baxter 1999</a>].</div></li><li class="half_rhythm"><div>A survey conducted in the Netherlands estimated a birth incidence of 1:396,000 [<a class="bk_pop" href="#pds.REF.been.2005.1293">Been et al 2005</a>].</div></li><li class="half_rhythm"><div>A study conducted in Germany, where pyridoxine administration is part of a standard treatment protocol for neonatal seizures, reported a birth incidence of probable cases of 1:20,000 [<a class="bk_pop" href="#pds.REF.ebinger.1999.795">Ebinger et al 1999</a>].</div></li></ul></div></div><div id="pds.Genetically_Related_Allelic_Disorder"><h2 id="_pds_Genetically_Related_Allelic_Disorder_">Genetically Related (Allelic) Disorders</h2><p><b>Folinic acid-responsive seizures</b>. A small number of infants with intractable seizures either unresponsive or partially responsive to pyridoxine but responsive to folinic acid (folinic acid-responsive seizures) have been described [<a class="bk_pop" href="#pds.REF.hyland.1995.177">Hyland et al 1995</a>, <a class="bk_pop" href="#pds.REF.torres.1999.529">Torres et al 1999</a>, <a class="bk_pop" href="#pds.REF.nicolai.2006.164">Nicolai et al 2006</a>]. Elevated levels of &#x003b1;-AASA and pathogenic variants in <i>ALDH7A1</i> have now been demonstrated in these children, indicating that folinic acid-responsive seizures are allelic to pyridoxine-dependent epilepsy [<a class="bk_pop" href="#pds.REF.gallagher.2009.550">Gallagher et al 2009</a>].</p></div><div id="pds.Differential_Diagnosis"><h2 id="_pds_Differential_Diagnosis_">Differential Diagnosis</h2><p>Pyridoxine-dependent epilepsy should be considered as a cause of intractable seizures presenting in neonates, infants, and children up to the third year of life for which an underlying lesion (i.e., symptomatic epilepsy) has not been identified. In particular, this diagnosis needs to be investigated in any neonate who presents with encephalopathy and seizures and in whom there is no convincing evidence of hypoxic-ischemic encephalopathy or other identifiable underlying metabolic disturbance [<a class="bk_pop" href="#pds.REF.baxter.1999.431">Baxter 1999</a>, <a class="bk_pop" href="#pds.REF.stockler.2011.48">Stockler et al 2011</a>].</p><div id="pds.Neonatal_and_Childhood_Epilepsy_Cond"><h3>Neonatal and Childhood Epilepsy Conditions</h3><p>Other causes of intractable neonatal seizures include the following:</p><ul><li class="half_rhythm"><div>"Folinic acid-responsive seizures" (see <a href="#pds.Genetically_Related_Allelic_Disorder">Genetically Related Disorders</a>)</div></li><li class="half_rhythm"><div>A variety of single <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> disorders that result in neonatal/infantile seizures; the products of these genes may underlie the function of ion channels, signaling pathways, and transcription factors, among others [<a class="bk_pop" href="#pds.REF.mastrangelo.2012.24">Mastrangelo &#x00026; Leuzzi 2012</a>]. In particular, <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals with pathogenic variants in <i>KCNQ2</i>, which encodes a neuronal potassium channel, may present with a neonatal epilepsy that does respond to treatment with pyridoxine [<a class="bk_pop" href="#pds.REF.mefford.2012.3190">Mefford et al 2012</a>, <a class="bk_pop" href="#pds.REF.reid.2016.79">Reid et al 2016</a>].</div></li><li class="half_rhythm"><div>Epileptic encephalopathies associated with copy number variants resulting in <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> deletions or duplications [<a class="bk_pop" href="#pds.REF.mefford.2011.974">Mefford et al 2011</a>]</div></li><li class="half_rhythm"><div>Lissencephaly or other brain malformations that are distinguishable by the presence of structural brain malformations (see <a href="/books/n/gene/fcmd/">Fukuyama Congenital Muscular Dystrophy</a>, <a href="/books/n/gene/dcx/"><i>DCX</i>-Related Disorders</a>, and <a href="/books/n/gene/chrom17-lis/"><i>LIS1</i>-Associated Lissencephaly/Subcortical Band Heterotopia</a>)</div></li><li class="half_rhythm"><div>Other rare inborn errors of metabolism that are identified by elevated ammonia, lactate, or anion gap on laboratory testing</div></li><li class="half_rhythm"><div>Severe acquired neurologic disorders such as intracerebral hemorrhage or infectious diseases (meningitis, encephalitis)</div></li></ul><p>Other causes of neonatal seizures in which elevated levels of &#x003b1;-AASA may be present:</p><ul><li class="half_rhythm"><div>Molybdenum cofactor deficiency (OMIM <a href="http://omim.org/entry/252150" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">252150</a>, <a href="http://omim.org/entry/252160" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">252160</a>, and <a href="http://omim.org/entry/615501" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">615501</a>). This heterogeneous group of conditions can be distinguished from PDE by the presence of increased urinary xanthine, hypoxanthine, and S-sulfocysteine [<a class="bk_pop" href="#pds.REF.mills.2012.1031">Mills et al 2012</a>, <a class="bk_pop" href="#pds.REF.struys.2012.e1716">Struys et al 2012</a>]. Molybdenum cofactor deficiency is caused by <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>MOCS1</i>, <i>MOCS2</i>, or <i>GPHN</i>. Inheritance is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>.</div></li><li class="half_rhythm"><div><a href="/books/n/gene/iso-def/">Isolated sulfite oxidase deficiency</a>. This condition can be distinguished from PDE by increased urinary sulfite and decreased urinary sulfate [<a class="bk_pop" href="#pds.REF.mills.2012.1031">Mills et al 2012</a>]. It is caused by <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>SUOX</i>; inheritance is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>.</div></li></ul><p><b>Epilepsy, early-onset, vitamin B<sub>6</sub>-dependent</b> (OMIM <a href="http://omim.org/entry/617290" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">617290</a>) is caused by <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>PROSC</i> (<i>pro</i>lone <i>s</i>ynthetase <i>c</i>o-transcribed homolog [bacterial]), which encodes a protein that is involved in the intracellular homeostatic regulation of pyridoxal 5&#x02019;-phosphate (PLP), the biologically active form of pyridoxine [<a class="bk_pop" href="#pds.REF.darin.2016.1325">Darin et al 2016</a>]. Seven individuals with this form of vitamin B<sub>6</sub>-dependent epilepsy have been reported (3 from 1 kindred) with six of the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals experiencing clinical seizures on the first day of life while the first seizure in the other affected individual occurred at age one month. During intrauterine life, three of the affected individuals were reported to have abnormal intrauterine movements; four showed signs of fetal distress, including metabolic acidosis with increased blood lactate levels noted within the first few days of life. While all seven demonstrated a clinical response to pyridoxine treatment, five of the six surviving affected individuals also require the use of antiepileptic drugs. With the exception of the one person whose seizures developed at age one month, all affected individuals have acquired microcephaly. All of the six surviving affected individuals have some degree of speech, motor, and learning developmental delays.</p><p><b>Pyridoxine-responsive seizures.</b> Some children with intractable seizures may have only partial improvement in seizure control with the addition of pyridoxine. In this situation, or in instances in which seizures recur after antiepileptic drugs are withdrawn and pyridoxine is continued, individuals who have not had molecular confirmation should not be diagnosed with pyridoxine-dependent epilepsy, but rather with "pyridoxine-responsive seizures" [<a class="bk_pop" href="#pds.REF.baxter.1999.431">Baxter 1999</a>, <a class="bk_pop" href="#pds.REF.basura.2009.697">Basura et al 2009</a>].</p><p><b>Inborn pyridoxine dependency states.</b> While other inborn pyridoxine dependency states have been described (e.g., pyridoxine-dependent anemia and pyridoxine-dependent forms of <a href="/books/n/gene/homocystinuria/">homocystinuria</a>, xanthurenic aciduria [OMIM <a href="http://omim.org/entry/236800" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">236800</a>], and cystathioninuria [OMIM <a href="http://omim.org/entry/219500" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">219500</a>]), these conditions are not genetically related to pyridoxine-dependent epilepsy.</p><p><b>Pyridoxal phosphate-responsive epilepsy (<i>PNPO</i> associated)</b> (OMIM <a href="http://omim.org/entry/610090" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">610090</a>), a rare form of <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> neonatal epileptic encephalopathy, is caused by <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>PNPO</i> (<i>PNPO</i> encodes an enzyme that interconverts the phosphorylated forms of pyridoxine and pyridoxamine to the biologically active pyridoxal 5&#x02019;-phosphate [PLP]). The initial reports of PNPO deficiency described infants with pharmacoresistant epileptic encephalopathy in whom the seizures responded to PLP but not to pyridoxine, suggesting that this disorder is clinically distinct from pyridoxine-dependent epilepsy [<a class="bk_pop" href="#pds.REF.mills.2005.1077">Mills et al 2005</a>, <a class="bk_pop" href="#pds.REF.hoffmann.2007.96">Hoffmann et al 2007</a>, <a class="bk_pop" href="#pds.REF.bagci.2008.f151">Bagci et al 2008</a>]. However, it was subsequently demonstrated that seizures in some individuals with PNPO deficiency actually responded to pyridoxine rather than to PLP [<a class="bk_pop" href="#pds.REF.pearl.2013.139">Pearl et al 2013</a>, <a class="bk_pop" href="#pds.REF.mills.2014.1350">Mills et al 2014</a>, <a class="bk_pop" href="#pds.REF.plecko.2014.1425">Plecko et al 2014</a>]. Therefore, persons with an epileptic encephalopathy responsive to pyridoxine who do not have pathogenic variants in <i>ALDH7A1</i> or <i>PROSC</i> should have <i>PNPO</i> <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>.</p><p><b>Other forms of pyridoxal phosphate-responsive epilepsy.</b> Other children with intractable epilepsy who show a clinical response to pyridoxal phosphate rather than to pyridoxine have been reported [<a class="bk_pop" href="#pds.REF.wang.2005.512">Wang et al 2005</a>]. The biochemical basis of the epileptic condition in these children has not been established [<a class="bk_pop" href="#pds.REF.baxter.2005.441">Baxter 2005</a>, <a class="bk_pop" href="#pds.REF.gospe.2006.148">Gospe 2006</a>].</p></div></div><div id="pds.Management"><h2 id="_pds_Management_">Management</h2><div id="pds.Evaluations_Following_Initial_Diagno"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with pyridoxine-dependent epilepsy, the following are appropriate:</p><ul><li class="half_rhythm"><div>Developmental assessment</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor</div></li></ul></div><div id="pds.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>In the majority of individuals with pyridoxine-dependent epilepsy, once seizures come under control with the addition of daily supplements of pyridoxine (see <a href="#pds.Prevention_of_Primary_Manifestations">Prevention of Primary Manifestations</a>), all antiepileptic drugs can be withdrawn, and seizure control will continue with daily pyridoxine monotherapy in pharmacologic doses.</p><p>Special education programs should be offered.</p></div><div id="pds.Prevention_of_Primary_Manifestations"><h3>Prevention of Primary Manifestations</h3><p>The effective treatment of individuals with pyridoxine-dependent epilepsy requires lifelong pharmacologic supplements of pyridoxine; the rarity of the disorder has precluded controlled studies to evaluate the optimal dose.</p><p>The recommended daily allowance (RDA) for pyridoxine is 0.5 mg for infants and 2 mg for adults. In general, individuals with pyridoxine-dependent epilepsy have excellent seizure control when treated with 50-100 mg of pyridoxine per day. Seizures in some individuals are controlled on much smaller doses and others require somewhat higher doses [<a class="bk_pop" href="#pds.REF.basura.2009.697">Basura et al 2009</a>, <a class="bk_pop" href="#pds.REF.stockler.2011.48">Stockler et al 2011</a>].</p><p>Affected individuals may have exacerbations of clinical seizures and/or encephalopathy during an acute illness, such as gastroenteritis or a febrile respiratory infection. To prevent such an exacerbation in these circumstances, the daily dose of pyridoxine may be doubled for several days until the acute illness resolves.</p><p>Studies have indicated that higher doses may enhance intellectual development; it has been suggested that a dose of 15-30 mg/kg/day may be optimal [<a class="bk_pop" href="#pds.REF.baxter.2001.416">Baxter 2001</a>, <a class="bk_pop" href="#pds.REF.stockler.2011.48">Stockler et al 2011</a>] and that the dosage should not exceed 500 mg/day [<a class="bk_pop" href="#pds.REF.stockler.2011.48">Stockler et al 2011</a>].</p><p>Such therapy is required for life; <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals are metabolically dependent on the vitamin, rather than pyridoxine deficient. Compliance with pyridoxine supplementation is critical, as status epilepticus may develop within days of pyridoxine discontinuation.</p></div><div id="pds.Prevention_of_Secondary_Complication"><h3>Prevention of Secondary Complications</h3><p>The overuse of pyridoxine must be avoided, as a reversible sensory neuropathy (ganglionopathy) caused by pyridoxine neurotoxicity can develop. While primarily reported in adults who have received "megavitamin therapy" with pyridoxine, sensory neuropathy has been reported in two persons with pyridoxine-dependent epilepsy [<a class="bk_pop" href="#pds.REF.mclachlan.1995.50">McLachlan &#x00026; Brown 1995</a>, <a class="bk_pop" href="#pds.REF.rankin.2007.300">Rankin et al 2007</a>], one of whom was an adolescent who developed a secondary cause of epilepsy and received a pyridoxine dose of 2 g/day [<a class="bk_pop" href="#pds.REF.mclachlan.1995.50">McLachlan &#x00026; Brown 1995</a>].</p></div><div id="pds.Surveillance"><h3>Surveillance</h3><p>Affected individuals should be followed for the development of clinical signs of a sensory neuropathy, including regular assessments of joint-position sense, ankle jerks, gait, and station [<a class="bk_pop" href="#pds.REF.baxter.2001.416">Baxter 2001</a>, <a class="bk_pop" href="#pds.REF.stockler.2011.48">Stockler et al 2011</a>].</p><p>Regular assessments of intellectual function should be offered.</p></div><div id="pds.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>Overuse of pyridoxine (see <b>Prevention of Secondary Complications</b>) is to be avoided.</p></div><div id="pds.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>Empiric treatment of the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual&#x02019;s newborn sib with pyridoxine supplementation should be offered until testing has been completed.</p><p>If the <i>ALDH7A1</i> pathogenic variants in the family are known, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> is appropriate.</p><p>If the pathogenic variants are not known, the following is recommended:</p><ul><li class="half_rhythm"><div>If a younger sib of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> presents with encephalopathy or a seizure, pyridoxine should be administered acutely (ideally under EEG monitoring) for both diagnostic and therapeutic purposes.</div></li><li class="half_rhythm"><div>&#x003b1;-AASA is a sensitive biomarker for pyridoxine-dependent epilepsy while pipecolic acid is an indirect and less sensitive biomarker. If elevated plasma biomarker concentrations have been demonstrated in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>, a similar elevation in a younger sib would support a diagnosis of pyridoxine-dependent epilepsy.</div></li></ul><p>Note: It would be unlikely for the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s older sibs who have not experienced seizures to be pyridoxine dependent.</p><p>See <a href="#pds.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="pds.Pregnancy_Management"><h3>Pregnancy Management</h3><p>As <a class="def" href="/books/n/gene/glossary/def-item/recurrence-risk/">recurrence risk</a> for couples who have a child with this disorder is 25%, there is justification to treat the mother empirically with supplemental pyridoxine at a dose of 50-100 mg/day throughout the last half of her subsequent pregnancies and to treat the newborn with supplemental pyridoxine to prevent seizures and reduce the risk of neurodevelopmental disability [<a class="bk_pop" href="#pds.REF.baxter.1999.2082">Baxter &#x00026; Aicardi 1999</a>, <a class="bk_pop" href="#pds.REF.bok.2010a.297">Bok et al 2010a</a>]. It is important to emphasize, however, that at least one severe <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> has been described in a family in which prenatal treatment of an at-risk sib did not result in an improved neurodevelopmental outcome [<a class="bk_pop" href="#pds.REF.rankin.2007.300">Rankin et al 2007</a>].</p><p>Molecular genetic testing of <i>ALDH7A1</i> can be performed prenatally or after birth; if both pathogenic variants are present, pyridoxine treatment should be continued during pregnancy (if prenatal testing is pursued and reveals the fetus to be <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>) and after birth; if not, treatment can be withdrawn.</p></div><div id="pds.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>As <i>ALDH7A1</i> encodes the enzyme &#x003b1;-aminoadipic semialdehyde dehydrogenase (antiquitin), which is involved in cerebral lysine catabolism, it has been proposed that persons with pyridoxine-dependent epilepsy may benefit from a lysine-restricted diet. A small number of individuals have been treated in this fashion; improvements in development and behavior along with decreased biomarker levels have been described [<a class="bk_pop" href="#pds.REF.stockler.2011.48">Stockler et al 2011</a>, <a class="bk_pop" href="#pds.REF.van_karnebeek.2012.335">van Karnebeek et al 2012</a>]. A protocol for controlled therapeutic trials of lysine restriction in pyridoxine-dependent epilepsy has recently been proposed [<a class="bk_pop" href="#pds.REF.van_karnebeek.2014.1">van Karnebeek et al 2014</a>].</p><p>L-arginine competitively inhibits lysine transport and can therefore reduce lysine levels. Some individuals with pyridoxine-dependent epilepsy have difficulty tolerating a lysine-restricted medical diet; in such cases L-arginine supplementation has been offered as an alternative method of lowering lysine levels [<a class="bk_pop" href="#pds.REF.mercimekmahmutoglu.2014.741">Mercimek-Mahmutoglu et al 2014</a>]. The effectiveness of treating pyridoxine-dependent epilepsy with "triple therapy" (a combination of pyridoxine supplementation, lysine restriction, and L-arginine supplementation) has also been studied [<a class="bk_pop" href="#pds.REF.coughlin.2015.35">Coughlin et al 2015</a>, <a class="bk_pop" href="#pds.REF.mahajnah.2016.60">Mahajnah et al 2016</a>], with promising results in a small number of treated individuals.</p><p>A cellular proof of concept for antisense therapy of pyridoxine-dependent epilepsy has been reported [<a class="bk_pop" href="#pds.REF.p_rez.2013.239">P&#x000e9;rez et al 2013</a>]. Specifically, the silent nucleotide change c.75C&#x0003e;T, a novel <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> variant creating a new donor <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 1, was rescued in a lymphoblast cell line via antisense therapy.</p><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.ClinicalTrialsRegister.eu" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ClinicalTrialsRegister.eu</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions.</p></div></div><div id="pds.Genetic_Counseling"><h2 id="_pds_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="pds.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Pyridoxine-dependent epilepsy is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner.</p></div><div id="pds.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The parents of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> child are obligate heterozygotes (i.e., carriers of one <i>ALDH7A1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>).</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier.</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</div></li><li class="half_rhythm"><div>Even if the sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> are asymptomatic, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> to determine their genetic status should be considered for the purpose of early diagnosis and treatment of those who have inherited both pathogenic variants (see <a href="#pds.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a>).</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Adults diagnosed with the disorder are being followed, but the fertility status of these individuals is not known, and there are no published reports concerning the offspring of individuals with pyridoxine-dependent epilepsy.</div></li><li class="half_rhythm"><div>Unless an individual with pyridoxine-dependent epilepsy has children with an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual or a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, his/her offspring will be obligate heterozygotes (carriers) for a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>ALDH7A1</i>.</div></li></ul><p><b>Other family members.</b> Each sib of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents is at a 50% risk of being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> of an <i>ALDH7A1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p></div><div id="pds.Carrier_Heterozygote_Detection"><h3>Carrier (Heterozygote) Detection</h3><p>Carrier testing for at-risk relatives requires prior identification of the <i>ALDH7A1</i> pathogenic variants in the family.</p></div><div id="pds.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#pds.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, are carriers, or are at risk of being carriers.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="pds.Prenatal_Testing_and_Preimplantation"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <i>ALDH7A1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> for pyridoxine-dependent epilepsy are possible.</p></div></div><div id="pds.Resources"><h2 id="_pds_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>American Epilepsy Society (AES)</b></div><div><a href="http://www.aesnet.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.aesnet.org</a></div></li><li class="half_rhythm"><div><b>Epilepsy Foundation</b></div><div>8301 Professional Place East</div><div>Suite 200</div><div>Landover MD 20785-7223</div><div><b>Phone:</b> 800-332-1000 (toll-free)</div><div><b>Email:</b> ContactUs@efa.org</div><div><a href="https://www.epilepsy.com/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.epilepsy.com</a></div></li><li class="half_rhythm"><div><b>International Pyridoxine Dependent Epilepsy Registry</b></div><div>PDE Consortium</div><div><b>Email:</b> pde@cw.bc.ca</div><div><a href="http://www.pdeonline.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.pdeonline.org</a></div></li></ul></div><div id="pds.Molecular_Genetics"><h2 id="_pds_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="pds.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Pyridoxine-Dependent Epilepsy: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1486/table/pds.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__pds.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_pds.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_pds.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_pds.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_pds.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_pds.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_pds.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_pds.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/501" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>ALDH7A1</i></a></td><td headers="hd_b_pds.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=501" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">5q23<wbr style="display:inline-block"></wbr>​.2</a></td><td headers="hd_b_pds.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P49419" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Alpha-aminoadipic semialdehyde dehydrogenase</a></td><td headers="hd_b_pds.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/ALDH7A1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ALDH7A1 database</a></td><td headers="hd_b_pds.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=ALDH7A1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ALDH7A1</a></td><td headers="hd_b_pds.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=ALDH7A1[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ALDH7A1</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="pds.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="pds.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Pyridoxine-Dependent Epilepsy (<a href="/omim/107323,266100" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1486/table/pds.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__pds.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/107323" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">107323</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">ALDEHYDE DEHYDROGENASE 7 FAMILY, MEMBER A1; ALDH7A1</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/266100" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">266100</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EPILEPSY, PYRIDOXINE-DEPENDENT; EPD</td></tr></tbody></table></div></div><div id="pds.Molecular_Genetic_Pathogenesis"><h3>Molecular Genetic Pathogenesis</h3><p>For many years, it was hypothesized that pyridoxine-dependent epilepsy was caused by an abnormality of the enzyme glutamic acid decarboxylase (GAD), which uses PLP as a cofactor. GAD converts glutamic acid, an excitatory neurotransmitter, into gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter. Both of these neurotransmitters play important roles in the control of epileptic processes. A number of clinical neurochemical studies indirectly supported this hypothesis. However, several laboratories failed to document genetic linkage of the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> to either isoform of GAD [<a class="bk_pop" href="#pds.REF.kure.1998.128">Kure et al 1998</a>, <a class="bk_pop" href="#pds.REF.battaglioli.2000.309">Battaglioli et al 2000</a>, <a class="bk_pop" href="#pds.REF.cormierdaire.2000.991">Cormier-Daire et al 2000</a>].</p><p>A genome-wide linkage scan of five families of North African descent (4 of whom were <a class="def" href="/books/n/gene/glossary/def-item/consanguineous/">consanguineous</a>) mapped a <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> for pyridoxine-dependent epilepsy at <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> 5q31 [<a class="bk_pop" href="#pds.REF.cormierdaire.2000.991">Cormier-Daire et al 2000</a>]. <i>ALDH7A1</i> maps to this region. Pathogenic variants in <i>ALDH7A1</i> have been demonstrated to cause pyridoxine-dependent epilepsy. <i>ALDH7A1</i> encodes the protein &#x003b1;-aminoadipic semialdehyde dehydrogenase (also referred to as antiquitin), an aldehyde dehydrogenase with a previously unknown physiologic substrate [<a class="bk_pop" href="#pds.REF.lee.1994.371">Lee et al 1994</a>]. It has now been demonstrated that antiquitin functions as a &#x00394;<sup>1</sup>-piperideine-6-carboxylate (P6C)-&#x003b1;-AASA dehydrogenase. Abnormal activity of this enzyme results in increased levels of P6C, which is the cyclic Schiff base of &#x003b1;-AASA; these two substances are in equilibrium with one another. P6C, in turn, inactivates PLP by condensing with the cofactor, likely resulting in abnormal metabolism of neurotransmitters [<a class="bk_pop" href="#pds.REF.mills.2006.307">Mills et al 2006</a>]. Antiquitin has been shown to localize to radial glia, astrocytes, and ependymal cells but not to neurons. Deficiency of this protein in pyridoxine-dependent epilepsy is associated with neuronal migration abnormalities and other forms of brain dysgenesis, such as thinning of the corpus callosum [<a class="bk_pop" href="#pds.REF.friedman.2014.1106">Friedman et al 2014</a>, <a class="bk_pop" href="#pds.REF.jansen.2014.22">Jansen et al 2014</a>, <a class="bk_pop" href="#pds.REF.marguet.2016.1435">Marguet et al 2016</a>, <a class="bk_pop" href="#pds.REF.poliachik.2016.43">Poliachik et al 2016</a>]. These neurodevelopmental aspects of antiquitin deficiency are not reversible with pyridoxine treatment, lysine restriction, or L-arginine supplementation.</p><p><b>Gene structure.</b>
<i>ALDH7A1</i> has 1809 bases and comprises 18 exons that range from 42 bp to 352 bp in size. The <a class="def" href="/books/n/gene/glossary/def-item/coding-region/">coding region</a> is 1533 bp in length. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1486/#pds.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> Pathogenic variants have been documented in numerous <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> families (see <a class="figpopup" href="/books/NBK1486/table/pds.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="figpdsTmoleculargenetictestingusedin" rid-ob="figobpdsTmoleculargenetictestingusedin">Table 1</a>). These include a variety of <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants, single-base deletions, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> variants (probably leading to nonsense-mediated <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> decay), <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants (predicted to cause <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> skipping), and exon deletions. Individuals who are either <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for a particular <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> or <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a> for two pathogenic variants have been reported [<a class="bk_pop" href="#pds.REF.mills.2006.307">Mills et al 2006</a>, <a class="bk_pop" href="#pds.REF.kanno.2007.384">Kanno et al 2007</a>, <a class="bk_pop" href="#pds.REF.plecko.2007.19">Plecko et al 2007</a>, <a class="bk_pop" href="#pds.REF.rankin.2007.300">Rankin et al 2007</a>, <a class="bk_pop" href="#pds.REF.salomons.2007.414">Salomons et al 2007</a>, <a class="bk_pop" href="#pds.REF.kluger.2008.276">Kluger et al 2008</a>, <a class="bk_pop" href="#pds.REF.bennett.2009.1167">Bennett et al 2009</a>, Gallagher et all 2009, <a class="bk_pop" href="#pds.REF.striano.2009.933">Striano et al 2009</a>, <a class="bk_pop" href="#pds.REF.mills.2010.2148">Mills et al 2010</a>, <a class="bk_pop" href="#pds.REF.scharer.2010.571">Scharer et al 2010</a>, <a class="bk_pop" href="#pds.REF.bok.2012.849">Bok et al 2012</a>, <a class="bk_pop" href="#pds.REF.p_rez.2013.239">P&#x000e9;rez et al 2013</a>, <a class="bk_pop" href="#pds.REF.tlili.2013.242">Tlili et al 2013</a>, <a class="bk_pop" href="#pds.REF.mefford.2015.756">Mefford et al 2015</a>].</p><p>Nine pathogenic variants represent 61% of disease alleles and several studies have demonstrated that the glutamine 399 residue is mutated at a frequency of 33%, with the p.Glu399Gln (<a href="/nuccore/66348118" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_001182.2</a>:c.1195G&#x0003e;C) <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> being most common [<a class="bk_pop" href="#pds.REF.plecko.2007.19">Plecko et al 2007</a>, <a class="bk_pop" href="#pds.REF.salomons.2007.414">Salomons et al 2007</a>, <a class="bk_pop" href="#pds.REF.bennett.2009.1167">Bennett et al 2009</a>, <a class="bk_pop" href="#pds.REF.mills.2010.2148">Mills et al 2010</a>, <a class="bk_pop" href="#pds.REF.scharer.2010.571">Scharer et al 2010</a>, <a class="bk_pop" href="#pds.REF.bok.2012.849">Bok et al 2012</a>]. Exon 7 was involved in three of eight kindreds with pathogenic <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions in <i>ALDH7A1</i>, suggesting that exon 7 may be somewhat prone to <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> [<a class="bk_pop" href="#pds.REF.plecko.2007.19">Plecko et al 2007</a>, <a class="bk_pop" href="#pds.REF.mefford.2015.756">Mefford et al 2015</a>].</p><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>ALDH7A1</i> encodes a protein with 510 amino-acid residues [<a class="bk_pop" href="#pds.REF.mills.2006.307">Mills et al 2006</a>]. The deduced molecular weight of the encoded &#x00394;<sup>1</sup>-piperideine-6-carboxylate (P6C)-&#x003b1;-AASA dehydrogenase protein (antiquitin) is 55285 [<a class="bk_pop" href="#pds.REF.lee.1994.371">Lee et al 1994</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> In one study, the two <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants, one <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> variant, and the one documented single-base <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> all result in absent &#x003b1;-AASA dehydrogenase enzyme activity while the second nonsense variant resulted in &#x003b1;-AASA dehydrogenase enzyme activity that was 1.8% of normal [<a class="bk_pop" href="#pds.REF.mills.2006.307">Mills et al 2006</a>]. The effect of selected <i>ALDH7A1</i> pathogenic variants on antiquitin function has been studied by expressing human antiquitin <a class="def" href="/books/n/gene/glossary/def-item/cdna/">cDNA</a> in <i>E coli</i> with reduced or absent enzyme activity being demonstrated [<a class="bk_pop" href="#pds.REF.coultermackie.2012.478">Coulter-Mackie et al 2012</a>, <a class="bk_pop" href="#pds.REF.coultermackie.2014.462">Coulter-Mackie et al 2014</a>]. This experimental system may help characterize the pathogenicity of <i>ALDH7A1</i> variants. Molecular modeling indicates that missense variants are divided into three categories [<a class="bk_pop" href="#pds.REF.scharer.2010.571">Scharer et al 2010</a>]:</p><ul><li class="half_rhythm"><div>Variants that affect NAD+ cofactor binding or catalysis;</div></li><li class="half_rhythm"><div>Variants that alter the substrate binding pocket; and</div></li><li class="half_rhythm"><div>Variants that potentially disrupt dimer or tetramer assembly of the antiquitin protein.</div></li></ul></div></div><div id="pds.References"><h2 id="_pds_References_">References</h2><div id="pds.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="pds.REF.bagci.2008.f151">Bagci S, Zschocke J, Hoffmann GF, Bast T, Klepper J, Muller A, Heep A, Bartmann P, Franz AR. Pyridoxal phosphate-dependent neonatal epileptic encephalopathy. <span><span class="ref-journal">Arch Dis Child Fetal Neonatal Ed. </span>2008;<span class="ref-vol">93</span>:F151–2.</span> [<a href="/pubmed/18296573" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18296573</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pds.REF.basura.2009.697">Basura GJ, Hagland SP, Wiltse AM, Gospe SM Jr. Clinical features and the management of pyridoxine-dependent and pyridoxine-responsive seizures: review of 63 North American cases submitted to a patient registry. <span><span class="ref-journal">Eur J Pediatr. </span>2009;<span class="ref-vol">168</span>:697–704.</span> [<a href="/pubmed/18762976" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18762976</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pds.REF.battaglioli.2000.309">Battaglioli G, Rosen DR, Gospe SM Jr, Martin DL. Glutamate decarboxylase is not genetically linked to pyridoxine-dependent seizures. <span><span class="ref-journal">Neurology. </span>2000;<span class="ref-vol">55</span>:309–11.</span> [<a href="/pubmed/10908915" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10908915</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pds.REF.baxter.1999.431">Baxter P. Epidemiology of pyridoxine dependent and pyridoxine responsive seizures in the UK. <span><span class="ref-journal">Arch Dis Child. </span>1999;<span class="ref-vol">81</span>:431–3.</span> [<a href="/pmc/articles/PMC1718118/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1718118</span></a>] [<a href="/pubmed/10519720" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10519720</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pds.REF.baxter.2001.416">Baxter P. Pyridoxine-dependent and pyridoxine-responsive seizures. <span><span class="ref-journal">Dev Med Child Neurol. </span>2001;<span class="ref-vol">43</span>:416–20.</span> [<a href="/pubmed/11409832" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11409832</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pds.REF.baxter.2005.441">Baxter P. Pyridoxine or pyridoxal phosphate for intractable seizures? <span><span class="ref-journal">Arch Dis Child. </span>2005;<span class="ref-vol">90</span>:441–2.</span> [<a href="/pmc/articles/PMC1720402/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1720402</span></a>] [<a href="/pubmed/15851419" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15851419</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pds.REF.baxter.1999.2082">Baxter P, Aicardi J. Neonatal seizures after pyridoxine use. <span><span class="ref-journal">Lancet. </span>1999;<span class="ref-vol">354</span>:2082–3.</span> [<a href="/pubmed/10636399" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10636399</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pds.REF.baxter.1996.998">Baxter P, Griffiths P, Kelly T, Gardner-Medwin D. Pyridoxine-dependent seizures: demographic, clinical, MRI and psychometric features, and effect of dose on intelligence quotient. <span><span class="ref-journal">Dev Med Child Neurol. </span>1996;<span class="ref-vol">38</span>:998–1006.</span> [<a href="/pubmed/8913181" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8913181</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pds.REF.baynes.2003.782">Baynes K, Farias ST, Gospe SM Jr. Pyridoxine-dependent seizures and cognition in adulthood. <span><span class="ref-journal">Dev Med Child Neurol. </span>2003;<span class="ref-vol">45</span>:782–5.</span> [<a href="/pubmed/14580135" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14580135</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pds.REF.been.2005.1293">Been JV, Bok JA, Andriessen P, Renier WO. Epidemiology of pyridoxine dependent seizures in The Netherlands. <span><span class="ref-journal">Arch Dis Child. </span>2005;<span class="ref-vol">90</span>:1293–6.</span> [<a href="/pmc/articles/PMC1720231/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1720231</span></a>] [<a href="/pubmed/16159904" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16159904</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pds.REF.bennett.2009.1167">Bennett CL, Chen Y, Hahn S, Glass IA, Gospe SM Jr. Prevalence of ALDH7A1 mutations in 18 North American pyridoxine-dependent seizure (PDS) patients. <span><span class="ref-journal">Epilepsia. </span>2009;<span class="ref-vol">50</span>:1167–75.</span> [<a href="/pubmed/19128417" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19128417</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pds.REF.bennett.2005.143">Bennett CL, Huynh HM, Chance PF, Glass IA, Gospe SM Jr. Genetic heterogeneity for autosomal recessive pyridoxine-dependent seizures. <span><span class="ref-journal">Neurogenetics. </span>2005;<span class="ref-vol">6</span>:143–9.</span> [<a href="/pubmed/16075246" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16075246</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pds.REF.bok.2010a.297">Bok LA, Been JV, Struys EA, Jakobs C, Rijper EA, Willemsen MA. Antenatal treatment in two Dutch families with pyridoxine-dependent seizures. <span><span class="ref-journal">Eur J Pediatr. </span>2010a;<span class="ref-vol">169</span>:297–303.</span> [<a href="/pubmed/19588165" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19588165</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pds.REF.bok.2012.849">Bok LA, Halbertsma FJ, Houterman S, Wevers RA, Vreeswijk C, Jakobs C, Struys E, Van Der Hoeven JH, Sival DA, Willemsen MA. Long-term outcome in pyridoxine dependent epilepsy. <span><span class="ref-journal">Dev Med Child Neurol. </span>2012;<span class="ref-vol">54</span>:849–54.</span> [<a href="/pubmed/22804844" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22804844</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pds.REF.bok.2010b.2406">Bok LA, Maurits NM, Willemsen MA, Jakobs C, Teune LK, Poll-The BT, de Coo IF, Toet MC, Hagebeuk EE, Brouwer OF, van der Hoeven JH, Sival DA. The EEG response to pyridoxine-IV neither identifies nor excludes pyridoxine-dependent epilepsy. <span><span class="ref-journal">Epilepsia. </span>2010b;<span class="ref-vol">51</span>:2406–11.</span> [<a href="/pubmed/20887371" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20887371</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pds.REF.coker.1992.221">Coker SB. Postneonatal vitamin B6-dependent epilepsy. <span><span class="ref-journal">Pediatrics. </span>1992;<span class="ref-vol">90</span>:221–3.</span> [<a href="/pubmed/1641285" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1641285</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pds.REF.cormierdaire.2000.991">Cormier-Daire V, Dagoneau N, Nabbout R, Burglen L, Penet C, Soufflet C, Desguerre I, Munnich A, Dulac O. A gene for pyridoxine-dependent epilepsy maps to chromosome 5q31. <span><span class="ref-journal">Am J Hum Genet. </span>2000;<span class="ref-vol">67</span>:991–3.</span> [<a href="/pmc/articles/PMC1287902/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1287902</span></a>] [<a href="/pubmed/10978228" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10978228</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pds.REF.coughlin.2015.35">Coughlin CR 2nd, van Karnebeek CD, Al-Hertani W, Shuen AY, Jaggumantri S, Jack RM, Gaughan S, Burns C, Mirsky DM, Gallagher RC, Van Hove JL. Triple therapy with pyridoxine, arginine supplementation and dietary lysine restriction in pyridoxine-dependent epilepsy: neurodevelopmental outcome. <span><span class="ref-journal">Mol Genet Metab. </span>2015;<span class="ref-vol">116</span>:35–43.</span> [<a href="/pubmed/26026794" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26026794</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pds.REF.coultermackie.2012.478">Coulter-Mackie MB, Li A, Lian Q, Struys E, St&#x000f6;ckler S, Waters PJ. Overexpression of human antiquitin in E. coli: enzymatic characterization of twelve ALDH7A1 missense mutations associated with pyridoxine-dependent epilepsy. <span><span class="ref-journal">Mol Genet Metab. </span>2012;<span class="ref-vol">106</span>:478–81.</span> [<a href="/pubmed/22784480" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22784480</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pds.REF.coultermackie.2014.462">Coulter-Mackie MB, Tiebout S, van Karnebeek C, Stockler S. Overexpression of recombinant human antiquitin in E. coli: partial enzyme activity in selected ALDH7A1 missense mutations associated with pyridoxine-dependent epilepsy. <span><span class="ref-journal">Mol Genet Metab. </span>2014;<span class="ref-vol">111</span>:462–466.</span> [<a href="/pubmed/24613284" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24613284</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pds.REF.darin.2016.1325">Darin N, Reid E, Prunetti L, Samuelsson L, Husain RA, Wilson M, El Yacoubi B, Footitt E, Chong WK, Wilson LC, Prunty H, Pope S, Heales S, Lascelles K, Champion M, Wassmer E, Veggiotti P, de Cr&#x000e9;cy-Lagard V, Mills PB, Clayton PT. Mutations in PROSC disrupt cellular pyridoxal phosphate homeostasis and cause vitamin-B6-dependent epilepsy. <span><span class="ref-journal">Am J Hum Genet. </span>2016;<span class="ref-vol">99</span>:1325–37.</span> [<a href="/pmc/articles/PMC5142116/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5142116</span></a>] [<a href="/pubmed/27912044" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27912044</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pds.REF.ebinger.1999.795">Ebinger M, Schutze C, Konig S. Demographics and diagnosis of pyridoxine-dependent seizures. <span><span class="ref-journal">J Pediatr. </span>1999;<span class="ref-vol">134</span>:795–6.</span> [<a href="/pubmed/10356240" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10356240</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pds.REF.friedman.2014.1106">Friedman SD, Ishak GE, Poliachik S, Poliakov A, Otto RK, Shaw DWW, Willemsen MA, Bok LA, Gospe SM. Callosal alterations in pyridoxine-dependent epilepsy. <span><span class="ref-journal">Dev Med Child Neurol. </span>2014;<span class="ref-vol">56</span>:1106–10.</span> [<a href="/pubmed/24942048" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24942048</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pds.REF.gallagher.2009.550">Gallagher RC, Van Hove JL, Scharer G, Hyland K, Plecko B, Waters PJ, Mercimek-Mahmutoglu S, Stockler-Ipsiroglu S, Salomons GS, Rosenberg EH, Struys EA, Jakobs C. Folinic acid-responsive seizures are identical to pyridoxine-dependent epilepsy. <span><span class="ref-journal">Ann Neurol. </span>2009;<span class="ref-vol">65</span>:550–6.</span> [<a href="/pubmed/19142996" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19142996</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pds.REF.gospe.2006.148">Gospe SM Jr. Pyridoxine-dependent seizures: new genetic and biochemical clues to help with diagnosis and treatment. <span><span class="ref-journal">Curr Opin Neurol. </span>2006;<span class="ref-vol">19</span>:148–53.</span> [<a href="/pubmed/16538088" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16538088</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pds.REF.gouti_res.1985.117">Gouti&#x000e8;res F, Aicardi J. Atypical presentations of pyridoxine-dependent seizures: a treatable cause of intractable epilepsy in infants. <span><span class="ref-journal">Ann Neurol. </span>1985;<span class="ref-vol">17</span>:117–20.</span> [<a href="/pubmed/3977296" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3977296</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pds.REF.hoffmann.2007.96">Hoffmann GF, Schmitt B, Windfuhr M, Wagner N, Strehl H, Bagci S, Franz AR, Mills PB, Clayton PT, Baumgartner MR, Steinmann B, Bast T, Wolf NI, Zschocke J. Pyridoxal 5'-phosphate may be curative in early-onset epileptic encephalopathy. <span><span class="ref-journal">J Inherit Metab Dis. </span>2007;<span class="ref-vol">30</span>:96–9.</span> [<a href="/pubmed/17216302" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17216302</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pds.REF.hunt.1954.140">Hunt AD Jr, Stokes J Jr, McCrory WW, Stroud HH. Pyridoxine dependency: report of a case of intractable convulsions in an infant controlled by pyridoxine. <span><span class="ref-journal">Pediatrics. </span>1954;<span class="ref-vol">13</span>:140–5.</span> [<a href="/pubmed/13133562" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 13133562</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pds.REF.hyland.1995.177">Hyland K, Buist NR, Powell BR, Hoffman GF, Rating D, McGrath J, Acworth IN. Folinic acid responsive seizures: a new syndrome? <span><span class="ref-journal">J Inherit Metab Dis. </span>1995;<span class="ref-vol">18</span>:177–81.</span> [<a href="/pubmed/7564240" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7564240</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pds.REF.jansen.2014.22">Jansen LA, Hevner RF, Roden WH, Hahn SH, Jung S, Gospe SM Jr. Glial localization of antiquitin: Implications for pyridoxine-dependent epilepsy. <span><span class="ref-journal">Ann Neurol. </span>2014;<span class="ref-vol">75</span>:22–32.</span> [<a href="/pmc/articles/PMC3945410/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3945410</span></a>] [<a href="/pubmed/24122892" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24122892</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pds.REF.jung.2013.237">Jung S, Tran NT, Gospe SM Jr, Hahn SH. Preliminary investigation of the use of newborn dried blood spots for screening pyridoxine-dependent epilepsy by LC-MS/MS. <span><span class="ref-journal">Mol Genet Metab. </span>2013;<span class="ref-vol">110</span>:237–40.</span> [<a href="/pubmed/23953072" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23953072</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pds.REF.kabakus.2008.703">Kabakus N, Aydin M, Ugur SA, Durukan M, Tolun A. Very-late-onset pyridoxine-dependent seizures not linking to the known 5q31 locus. <span><span class="ref-journal">Pediatr Int. </span>2008;<span class="ref-vol">50</span>:703–5.</span> [<a href="/pubmed/19261126" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19261126</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pds.REF.kanno.2007.384">Kanno J, Kure S, Narisawa A, Kamada F, Takayanagi M, Yamamoto K, Hoshino H, Goto T, Takahashi T, Haginoya K, Tuschiya S, Baumeister FAM, Hasegawa Y, Aoki Y, Yamaguchi S, Matsubara Y. Allelic and non-allelic heterogeneities in pyridoxine dependent seizures revealed by ALDH7A1 mutational analysis. <span><span class="ref-journal">Mol Genet Metab. </span>2007;<span class="ref-vol">91</span>:384–9.</span> [<a href="/pubmed/17433748" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17433748</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pds.REF.kluger.2008.276">Kluger G, Blank R, Paul K, Paschke E, Jansen E, Jakobs C, W&#x000f6;rle H, Plecko B. Pyridoxine-dependent epilepsy: normal outcome in a patient with late diagnosis after prolonged status epilepticus causing cortical blindness. <span><span class="ref-journal">Neuropediatrics. </span>2008;<span class="ref-vol">39</span>:276–9.</span> [<a href="/pubmed/19294602" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19294602</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pds.REF.kure.1998.128">Kure S, Sakata Y, Miyabayashi S, Takahashi K, Shinka T, Matsubara Y, Hoshino H, Narisawa K. Mutation and polymorphic marker analyses of 65K- and 67K-glutamate decarboxylase genes in two families with pyridoxine-dependent epilepsy. <span><span class="ref-journal">J Hum Genet. </span>1998;<span class="ref-vol">43</span>:128–31.</span> [<a href="/pubmed/9621518" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9621518</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pds.REF.lee.1994.371">Lee P, Kuhl W, Gelbart T, Kamimura T, West C, Beutler E. Homology between a human protein and a protein of the green garden pea. <span><span class="ref-journal">Genomics. </span>1994;<span class="ref-vol">21</span>:371–8.</span> [<a href="/pubmed/8088832" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8088832</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pds.REF.mahajnah.2016.60">Mahajnah M, Corderio D, Austin V, Herd S, Mutch C, Carter M, Struys E, Mercimek-Mahmutoglu S. A prospective case study of the safety and efficacy of lysine-restricted diet and arginine supplementation therapy in a patient with pyridoxine-dependent epilepsy caused by mutations in ALDH7A1. <span><span class="ref-journal">Pediatr Neurol. </span>2016;<span class="ref-vol">60</span>:60–5.</span> [<a href="/pubmed/27212567" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27212567</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pds.REF.mercimekmahmutoglu.2014.741">Mercimek-Mahmutoglu S, Cordeiro D, Cruz V, Hyland K, Struys EA, Kyriakopoulou L, Mamak E. Novel therapy for pyridoxine dependent epilepsy due to ALDH7A1 genetic defect: L-arginine supplementation alternative to lysine-restricted diet. <span><span class="ref-journal">Eur J Paediatr Neurol. </span>2014;<span class="ref-vol">18</span>:741–6.</span> [<a href="/pubmed/25127453" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25127453</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pds.REF.marguet.2016.1435">Marguet F, Barakizou H, Tebani A, Abily-Donval L, Torre S, Bayoudh F, Jebnoun S, Brasseur-Daudruy M, Marret S, Laquerriere A, Bekri S. Pyridoxine-dependent epilepsy: report on three families with neuropathology. <span><span class="ref-journal">Metab Brain Dis. </span>2016;<span class="ref-vol">31</span>:1435–43.</span> [<a href="/pubmed/27438048" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27438048</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pds.REF.mastrangelo.2012.24">Mastrangelo M, Leuzzi V. Genes of early-onset epileptic encephalopathies: from genotype to phenotype. <span><span class="ref-journal">Pediatr Neurol. </span>2012;<span class="ref-vol">46</span>:24–31.</span> [<a href="/pubmed/22196487" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22196487</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pds.REF.mclachlan.1995.50">McLachlan RS, Brown WF. Pyridoxine dependent epilepsy with iatrogenic sensory neuronopathy. <span><span class="ref-journal">Can J Neurol Sci. </span>1995;<span class="ref-vol">22</span>:50–1.</span> [<a href="/pubmed/7750075" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7750075</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pds.REF.mefford.2012.3190">Mefford HC, Cook J, Gospe SM Jr. Epilepsy due to 20q13.33 subtelomere deletion masquerading as pyridoxine-dependent epilepsy. <span><span class="ref-journal">Am J Med Genet A. </span>2012;<span class="ref-vol">158A</span>:3190–5.</span> [<a href="/pubmed/23166088" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23166088</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pds.REF.mefford.2011.974">Mefford HC, Yendle SC, Hsu C, Cook J, Geraghty E, McMahon JM, Eeg-Olofsson O, Sadleir LG, Gill D, Ben-Zeev B, Lerman-Sagie T, Mackay M, Freeman JL, Andermann E, Pelakanos JT, Andrews I, Wallace G, Eichler EE, Berkovic SF, Scheffer IE. Rare copy number variants are an important cause of epileptic encephalopathies. <span><span class="ref-journal">Ann Neurol. </span>2011;<span class="ref-vol">70</span>:974–85.</span> [<a href="/pmc/articles/PMC3245646/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3245646</span></a>] [<a href="/pubmed/22190369" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22190369</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pds.REF.mefford.2015.756">Mefford HC, Zemel M, Geraghty E, Cook J, Clayton PT, Paul K, Plecko B, Mills PB, Nordli DR Jr, Gospe SM Jr. Intragenic deletions of ALDH7A1 in pyridoxine-dependent epilepsy caused by Alu-Alu recombination. <span><span class="ref-journal">Neurology. </span>2015;<span class="ref-vol">85</span>:756–62.</span> [<a href="/pmc/articles/PMC4553021/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4553021</span></a>] [<a href="/pubmed/26224730" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26224730</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pds.REF.mikati.1991.215">Mikati MA, Trevathan E, Krishnamoorthy KS, Lombroso CT. Pyridoxine-dependent epilepsy: EEG investigations and long-term follow-up. <span><span class="ref-journal">Electroencephalogr Clin Neurophysiol. </span>1991;<span class="ref-vol">78</span>:215–21.</span> [<a href="/pubmed/1707793" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1707793</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pds.REF.mills.2014.1350">Mills PB, Camuzeaux SS, Footitt EJ, Mills KA, Gissen P, Fisher L, Das KB, Varadkar SM, Zuberi S, McWilliam R, St&#x000f6;dberg T, Plecko B, Baumgartner MR, Maier O, Calvert S, Riney K, Wolf NI, Livingston JH, Bala P, Morel CF, Feillet F, Raimondi F, Del Giudice E, Chong WK, Pitt M, Clayton PT. Epilepsy due to PNPO mutations: genotype, environment and treatment affect presentation and outcome. <span><span class="ref-journal">Brain. </span>2014;<span class="ref-vol">137</span>:1350–60.</span> [<a href="/pmc/articles/PMC3999720/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3999720</span></a>] [<a href="/pubmed/24645144" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24645144</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pds.REF.mills.2012.1031">Mills PB, Footitt EJ, Ceyhan S, Waters PJ, Jakobs C, Clayton PT, Struys EA. Urinary AASA excretion is elevated in patients with molybdenum cofactor deficiency and isolated sulphite oxidase deficiency. <span><span class="ref-journal">J Inherit Metab Dis. </span>2012;<span class="ref-vol">35</span>:1031–6.</span> [<a href="/pubmed/22403017" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22403017</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pds.REF.mills.2006.307">Mills PB, Struys E, Jakobs C, Plecko B, Baxter P, Baumgartner M, Willemsen MA, Omran H, Tacke U, Uhlenberg B, Weschke B, Clayton PT. Mutations in antiquitin in individuals with pyridoxine-dependent seizures. <span><span class="ref-journal">Nat Med. </span>2006;<span class="ref-vol">12</span>:307–9.</span> [<a href="/pubmed/16491085" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16491085</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pds.REF.mills.2005.1077">Mills PB, Surtees RA, Champion MP, Beesley CE, Dalton N, Scambler PJ, Heales SJ, Briddon A, Scheimberg I, Hoffmann GF, Zschocke J, Clayton PT. Neonatal epileptic encephalopathy caused by mutations in the PNPO gene encoding pyridox(am)ine 5'-phosphate oxidase. <span><span class="ref-journal">Hum Mol Genet. </span>2005;<span class="ref-vol">14</span>:1077–86.</span> [<a href="/pubmed/15772097" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15772097</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pds.REF.mills.2010.2148">Mills PB, Footitt EJ, Mills KA, Tuschl K, Aylett S, Varadkar S, Hemingway C, Marlow N, Rennie J, Baxter P, Dulac O, Nabbout R, Craigen WJ, Schmitt B, Feillet F, Christensen E, De Lonlay P, Pike MG, Hughes MI, Struys EA, Jakobs C, Zuberi SM, Clayton PT. Genotypic and phenotypic spectrum of pyridoxine-dependent epilepsy (ALDH7A1 deficiency). <span><span class="ref-journal">Brain. </span>2010;<span class="ref-vol">133</span>:2148–59.</span> [<a href="/pmc/articles/PMC2892945/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2892945</span></a>] [<a href="/pubmed/20554659" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20554659</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pds.REF.nabbout.1999.f125">Nabbout R, Soufflet C, Plouin P, Dulac O. Pyridoxine dependent epilepsy: a suggestive electroclinical pattern. <span><span class="ref-journal">Arch Dis Child Fetal Neonatal Ed. </span>1999;<span class="ref-vol">81</span>:F125–9.</span> [<a href="/pmc/articles/PMC1720985/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1720985</span></a>] [<a href="/pubmed/10448181" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10448181</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pds.REF.naasan.2009.293">Naasan G, Yabroudi M, Rahi A, Mikati MA. Electroencephalographic changes in pyridoxine-dependant epilepsy: new observations. <span><span class="ref-journal">Epileptic Disord. </span>2009;<span class="ref-vol">11</span>:293–300.</span> [<a href="/pubmed/20031502" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20031502</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pds.REF.nicolai.2006.164">Nicolai J, van Kranen-Mastenbroek VH, Wevers RA, Hurkx WA, Vles JS. Folinic acid-responsive seizures initially responsive to pyridoxine. <span><span class="ref-journal">Pediatr Neurol. </span>2006;<span class="ref-vol">34</span>:164–7.</span> [<a href="/pubmed/16458834" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16458834</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pds.REF.ohtsuka.1999.203">Ohtsuka Y, Hattori J, Ishida T, Ogino T, Oka E. Long-term follow-up of an individual with vitamin B6-dependent seizures. <span><span class="ref-journal">Dev Med Child Neurol. </span>1999;<span class="ref-vol">41</span>:203–6.</span> [<a href="/pubmed/10210253" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10210253</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pds.REF.pearl.2013.139">Pearl PL, Hyland K, Chiles J, McGavin CL, Yu Y, Taylor D. Partial Pyridoxine Responsiveness in PNPO Deficiency. <span><span class="ref-journal">JIMD Rep. </span>2013;<span class="ref-vol">9</span>:139–42.</span> [<a href="/pmc/articles/PMC3565675/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3565675</span></a>] [<a href="/pubmed/23430561" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23430561</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pds.REF.p_rez.2013.239">P&#x000e9;rez B, Guti&#x000e9;rrez-Solana LG, Verd&#x000fa; A, Merinero B, Yuste-Checa P, Ruiz-Sala P, Calvo R, Jalan A, Mar&#x000ed;n LL, Campos O, Ruiz M&#x000c1;, San Miguel M, V&#x000e1;zquez M, Castro M, Ferrer I, Navarrete R, Desviat LR, Lapunzina P, Ugarte M, P&#x000e9;rez-Cerd&#x000e1; C. Clinical, biochemical, and molecular studies in pyridoxine-dependent epilepsy. Antisense therapy as possible new therapeutic option. <span><span class="ref-journal">Epilepsia. </span>2013;<span class="ref-vol">54</span>:239–48.</span> [<a href="/pubmed/23350806" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23350806</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pds.REF.plecko.2005.200">Plecko B, Hikel C, Korenke GC, Schmitt B, Baumgartner M, Baumeister F, Jakobs C, Struys E, Erwa W, Stockler-Ipsiroglu S. Pipecolic acid as a diagnostic marker of pyridoxine-dependent epilepsy. <span><span class="ref-journal">Neuropediatrics. </span>2005;<span class="ref-vol">36</span>:200–5.</span> [<a href="/pubmed/15944906" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15944906</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pds.REF.plecko.2014.1425">Plecko B, Paul K, Mills P, Clayton P, Paschke E, Maier O, Hasselmann O, Schmiedel G, Kanz S, Connolly M, Wolf N, Struys E, Stockler S, Abela L, Hover D. Pyridoxine responsiveness in novel mutations of the PNPO gene. <span><span class="ref-journal">Neurology. </span>2014;<span class="ref-vol">82</span>:1425–33.</span> [<a href="/pmc/articles/PMC4001193/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4001193</span></a>] [<a href="/pubmed/24658933" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24658933</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pds.REF.plecko.2007.19">Plecko B, Paul K, Paschke E, Stoeckler-Ipsiroglu S, Struys E, Jakobs C, Hartmann H, Luecke T, di Capua M, Korenke C, Hikel C, Reutershahn E, Freilinger M, Baumeister F, Bosch F, Erwa W. Biochemical and molecular characterization of 18 patients with pyridoxine-dependent epilepsy and mutations of the antiquitin (ALDH7A1) gene. <span><span class="ref-journal">Hum Mutat. </span>2007;<span class="ref-vol">28</span>:19–26.</span> [<a href="/pubmed/17068770" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17068770</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pds.REF.poliachik.2016.43">Poliachik SL, Friedman SD, Poliakov AV, Budech CB, Ishak GE, Shaw DW, Gospe SM Jr. Corpus callosum diffusion and connectivity features in high functioning subjects with pyridoxine-dependent epilepsy. <span><span class="ref-journal">Pediatr Neurol. </span>2016;<span class="ref-vol">54</span>:43–8.</span> [<a href="/pubmed/26547255" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26547255</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pds.REF.rankin.2007.300">Rankin PM, Harrison S, Chong WK, Boyd S, Aylett SE. Pyridoxine-dependent seizures: a family phenotype that leads to severe cognitive deficits, regardless of treatment regime. <span><span class="ref-journal">Dev Med Child Neurol. </span>2007;<span class="ref-vol">49</span>:300–5.</span> [<a href="/pubmed/17376142" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17376142</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pds.REF.reid.2016.79">Reid ES, Williams H, Stabej Ple Q, James C, Ocaka L, Bacchelli C, Footitt EJ, Boyd S, Cleary MA, Mills PB, Clayton PT. Seizures due to a KCNQ2 mutation: treatment with vitamin B6. <span><span class="ref-journal">JIMD Rep. </span>2016;<span class="ref-vol">27</span>:79–84.</span> [<a href="/pmc/articles/PMC5580730/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5580730</span></a>] [<a href="/pubmed/26446091" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26446091</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pds.REF.salomons.2007.414">Salomons GS, Bok LA, Struys EA, Pope LL, Darmin PS, Mills PB, Clayton PT, Willemsen MA, Jakobs C. An intriguing "silent" mutation and a founder effect in antiquitin (ALDH7A1). <span><span class="ref-journal">Ann Neurol. </span>2007;<span class="ref-vol">62</span>:414–8.</span> [<a href="/pubmed/17721876" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17721876</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pds.REF.scharer.2010.571">Scharer G, Brocker C, Vasiliou V, Creadon-Swindell G, Gallagher RC, Spector E, Van Hove JL. The genotypic and phenotypic spectrum of pyridoxine-dependent epilepsy due to mutations in ALDH7A1. <span><span class="ref-journal">J Inherit Metab Dis. </span>2010;<span class="ref-vol">33</span>:571–81.</span> [<a href="/pmc/articles/PMC3112356/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3112356</span></a>] [<a href="/pubmed/20814824" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20814824</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pds.REF.schmitt.2010.e133">Schmitt B, Baumgartner M, Mills PB, Clayton PT, Jakobs C, Keller E, Wohlrab G. Seizures and paroxysmal events: symptoms pointing to the diagnosis of pyridoxine-dependent epilepsy and pyridoxine phosphate oxidase deficiency. <span><span class="ref-journal">Dev Med Child Neurol. </span>2010;<span class="ref-vol">52</span>:e133–42.</span> [<a href="/pubmed/20370816" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20370816</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pds.REF.stockler.2011.48">Stockler S, Plecko B, Gospe SM Jr, Coulter-Mackie M, Connolly M, van Karnebeek C, Mercimek-Mahmutoglu S, Hartmann H, Scharer G, Struijs E, Tein I, Jakobs C, Clayton P, Van Hove JL. Pyridoxine dependent epilepsy and antiquitin deficiency: clinical and molecular characteristics and recommendations for diagnosis, treatment and follow-up. <span><span class="ref-journal">Mol Genet Metab. </span>2011;<span class="ref-vol">104</span>:48–60.</span> [<a href="/pubmed/21704546" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21704546</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pds.REF.striano.2009.933">Striano P, Battaglia S, Giordano L, Capovilla G, Beccaria F, Struys EA, Salomons GS, Jakobs C. Two novel ALDH7A1 (antiquitin) splicing mutations associated with pyridoxine-dependent seizures. <span><span class="ref-journal">Epilepsia. </span>2009;<span class="ref-vol">50</span>:933–6.</span> [<a href="/pubmed/18717709" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18717709</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pds.REF.struys.2012.e1716">Struys EA, Nota B, Bakkali A, Al Shahwan S, Salomons GS, Tabarki B. Pyridoxine-dependent epilepsy with elevated urinary &#x003b1;-amino adipic semialdehyde in molybdenum cofactor deficiency. <span><span class="ref-journal">Pediatrics. </span>2012;<span class="ref-vol">130</span>:e1716–9.</span> [<a href="/pubmed/23147983" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23147983</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pds.REF.tlili.2013.242">Tlili A, Hamida Hentati N, Chaabane R, Gargouri A, Fakhfakh F. Pyridoxine-dependent epilepsy in Tunisia is caused by a founder missense mutation of the ALDH7A1 gene. <span><span class="ref-journal">Gene. </span>2013;<span class="ref-vol">518</span>:242–5.</span> [<a href="/pubmed/23376216" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23376216</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pds.REF.torres.1999.529">Torres OA, Miller VS, Buist NM, Hyland K. Folinic acid-responsive neonatal seizures. <span><span class="ref-journal">J Child Neurol. </span>1999;<span class="ref-vol">14</span>:529–32.</span> [<a href="/pubmed/10456764" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10456764</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pds.REF.van_karnebeek.2014.1">van Karnebeek CD, Stockler-Ipsiroglu S, Jaggumantri S, Assmann B, Baxter P, Buhas D, Bok LA, Cheng B, Coughlin CR 2nd, Das AM, Giezen A, Al-Hertani W, Ho G, Meyer U, Mills P, Plecko B, Struys E, Ueda K, Albersen M, Verhoeven N, Gospe SM Jr, Gallagher RC, Van Hove JK, Hartmann H. Lysine-restricted diet as adjunct therapy for pyridoxine-dependent epilepsy: The PDE Consortium Consensus Recommendations. <span><span class="ref-journal">JIMD Rep. </span>2014;<span class="ref-vol">15</span>:1–11.</span> [<a href="/pmc/articles/PMC4270869/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4270869</span></a>] [<a href="/pubmed/24748525" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24748525</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pds.REF.van_karnebeek.2015">van Karnebeek CD, Gospe SM Jr. Disorders of pyridoxine metabolism. In: Rosenberg E, Pascual J, eds. <em>Rosenberg&#x02019;s Molecular and Genetic Basis of Neurological and Psychiatric Disease.</em> 5 ed. Philadelphia, PA: Elsevier. 2015.</div></li><li class="half_rhythm"><div class="bk_ref" id="pds.REF.van_karnebeek.2012.335">van Karnebeek CD, Hartmann H, Jaggumantri S, Bok LA, Cheng B, Connolly M, Coughlin CR 2nd, Das AM, Gospe SM Jr, Jakobs C, van der Lee JH, Mercimek-Mahmutoglu S, Meyer U, Struys E, Sinclair G, Van Hove J, Collet JP, Plecko BR, Stockler S. Lysine restricted diet for pyridoxine-dependent epilepsy: first evidence and future trials. <span><span class="ref-journal">Mol Genet Metab. </span>2012;<span class="ref-vol">107</span>:335–44.</span> [<a href="/pubmed/23022070" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23022070</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pds.REF.van_karnebeek.2016.6">van Karnebeek CD, Tiebout SA, Niermeijer J, Poll-The BT, Ghani A, Coughlin CR 2nd, Van Hove JL, Richter JW, Christen HJ, Gallagher R, Hartmann H, Stockler-Ipsiroglu S. Pyridoxine-dependent epilepsy: an expanding clinical spectrum. <span><span class="ref-journal">Pediatr Neurol. </span>2016;<span class="ref-vol">59</span>:6–12.</span> [<a href="/pubmed/26995068" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26995068</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pds.REF.wang.2005.512">Wang HS, Chou ML, Hung PC, Lin KL, Hsieh MY, Chang MY. Pyridoxal phosphate is better than pyridoxine for controlling idiopathic intractable epilepsy. <span><span class="ref-journal">Arch Dis Child. </span>2005;<span class="ref-vol">90</span>:512–5.</span> [<a href="/pmc/articles/PMC1720393/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1720393</span></a>] [<a href="/pubmed/15851435" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15851435</span></a>]</div></li></ul></div></div><div id="pds.Chapter_Notes"><h2 id="_pds_Chapter_Notes_">Chapter Notes</h2><div id="pds.Author_Notes"><h3>Author Notes</h3><p><b>Pyridoxine-Dependent Epilepsy Patient Registry</b></p><p>For diagnosed patients, operated by the <a href="http://www.pdeonline.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PDE Consortium</a>. The registry may be contacted through the author or at pde@cw.bc.ca.</p></div><div id="pds.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>13 April 2017 (ma) Comprehensive update posted live</div></li><li class="half_rhythm"><div>19 June 2014 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>7 June 2012 (sg) Revision: <a class="figpopup" href="/books/NBK1486/table/pds.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="figpdsTmoleculargenetictestingusedin" rid-ob="figobpdsTmoleculargenetictestingusedin">Table 1</a> updated</div></li><li class="half_rhythm"><div>26 April 2012 (sg) Revision: additions to <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> table (<a class="figpopup" href="/books/NBK1486/table/pds.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="figpdsTmoleculargenetictestingusedin" rid-ob="figobpdsTmoleculargenetictestingusedin">Table 1</a>); references added</div></li><li class="half_rhythm"><div>1 March 2012 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>10 November 2009 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>24 July 2007 (cd) Revision: clinical testing available: <a class="def" href="/books/n/gene/glossary/def-item/analyte/">analyte</a> and <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>; <a class="def" href="/books/n/gene/glossary/def-item/prenatal-diagnosis/">prenatal diagnosis</a></div></li><li class="half_rhythm"><div>9 June 2006 (sg) Revision: mutations in <i>ALDH7A1</i> found to be causative</div></li><li class="half_rhythm"><div>8 March 2006 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>18 December 2003 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>7 December 2001 (me) Review posted live</div></li><li class="half_rhythm"><div>17 September 2001 (sg) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1486</span><span class="label">PMID: <a href="/pubmed/20301659" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301659</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/pf/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/pdc/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1486&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1486/?report=reader">PubReader</a></li><li><a href="/books/NBK1486/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1486" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1486" style="display:none" title="Cite this Page"><div class="bk_tt">Gospe SM Jr. Pyridoxine-Dependent Epilepsy. 2001 Dec 7 [Updated 2017 Apr 13]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1486/pdf/Bookshelf_NBK1486.pdf">PDF version of this page</a> (480K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#pds.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#pds.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#pds.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#pds.Genetically_Related_Allelic_Disorder" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#pds.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#pds.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#pds.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#pds.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#pds.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#pds.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#pds.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=501[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">ALDH7A1</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1499908" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1499908" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1499908" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1499908" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301603" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Glucose Transporter Type 1 Deficiency Syndrome</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Glucose Transporter Type 1 Deficiency Syndrome<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Wang D, Pascual JM, De Vivo D. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/24851285" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">KCNQ3</i>-Related Disorders</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">KCNQ3</i>-Related Disorders<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Miceli F, Soldovieri MV, Joshi N, Weckhuysen S, Cooper EC, Taglialatela M. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301294" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">ATP1A3-</i>Related Neurologic Disorders</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">ATP1A3-</i>Related Neurologic Disorders<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Brashear A, Sweadner KJ, Cook JF, Swoboda KJ, Ozelius L. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301697" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Homocystinuria Caused by Cystathionine Beta-Synthase Deficiency</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Homocystinuria Caused by Cystathionine Beta-Synthase Deficiency<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Sacharow SJ, Picker JD, Levy HL. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301494" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">SCN1A</i> Seizure Disorders</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">SCN1A</i> Seizure Disorders<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Miller IO, Sotero de Menezes MA. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301659" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301659" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e0419e4dd21425a25611c16">Pyridoxine-Dependent Epilepsy - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Pyridoxine-Dependent Epilepsy - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T21:24:36-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal101&amp;ncbi_phid=CE88CCE1E0409AD10000000006FF02B2&amp;ncbi_session=CE88CCE1E0419E41_1791SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1486%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1486&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1486/&amp;ncbi_pagename=Pyridoxine-Dependent Epilepsy - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE88CCE1E0419E41_1791SID /projects/books/PBooks@5.22 portal101 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>